- RESEARCH SUMMARY
Towards personalized treatment of smoking-related lung cancers
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-021-01113-9
References
Jamal-Hanjani, M. et al. N. Engl. J. Med. 376, 2109–2121 (2017).
Blakely, C. M. et al. Nature Genet. 49, 1693–1704 (2017).
Castiglione, R. et al. Mod. Pathol. 32, 627–638 (2019).
McFadden, D. G. et al. Proc. Natl Acad. Sci. USA 113, E6409–E6417 (2016).
Yuan, G. et al. Nature 590, 504–508 (2021).
Competing Interests
G.M. reported receiving research funding from Bristol-Myers Squibb, Kael-Gemvax, Merck Sharp & Dome and Plexxikon, and personal fees from BioLineRx, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dome and Roche.